Three Wall Street Darlings Analysts Love — And Why We're Skeptical
While sell-side analysts tout significant upside for Q2 Holdings, Teladoc Health, and Caleres, a closer look reveals potential pitfalls and valuation concerns that warrant caution from discerning investors.